Regulation of cell reprogramming by matrix stiffness
Regulation of cell reprogramming by matrix stiffness
批准号:
10491279
负责人:
Song Li
金额:
$32.48万
依托单位国家:
美国
项目类别:
财政年份:
2021
资助国家:
美国
项目状态:
未结题
起止时间:
2021-09-20 至 2025-07-31
关键词:
ActinsBiocompatible MaterialsBiologicalBiologyBiophysical ProcessBiophysicsCardiac MyocytesCell NucleusCell physiologyCellsCuesCytoskeletonDataDevelopmentDisease modelDistantDrug ScreeningEpigenetic ProcessExtracellular MatrixF-ActinFibroblastsFocal AdhesionsG ActinGene ExpressionGene TargetingGenesGenomicsHistone AcetylationMediatingMicrofilamentsModificationNeuronsNuclearNuclear TranslocationPhenotypePlayProcessRegenerative MedicineRegulationRoleSiteSomatic CellSurfaceTestingTissue EngineeringTransgenesWorkbasecell typecellular engineeringcofilindepolymerizationdesigndrug discoveryepigenomicsexperiencehistone acetyltransferaseinduced pluripotent stem celllive cell imagingmigrationmultidisciplinarynovelnovel strategiesnucleocytoplasmic transporttranscription factortranscriptomics
中文摘要
项目摘要
细胞重编程代表了生物学的一个重大进步,并且在生物学中具有广泛的应用。
再生医学、疾病建模和药物筛选。在细胞重编程过程中,细胞经历
表观遗传变化导致细胞表型转换。然而,生物物理因素是否以及如何
通过表观遗传修饰来调节细胞重编程还没有很好地理解。我们发现
生物物理因素,特别是细胞外基质(ECM)硬度,对表观遗传有深远的影响。
状态和成纤维细胞转化为诱导的神经元(iN)细胞,具有最高的效率,
中间ECM刚度,其由粘着斑和细胞骨架调节。另外我们
已经发现肌动蛋白组装和转运到细胞核中在表观遗传中起着重要作用,
调变基于我们的初步数据,我们假设(1)生物物理线索,如ECM
硬度调节脂肪酸,肌动蛋白组装/拆卸,肌动蛋白的核转运,因此,HAT活性,
调节表观遗传状态和细胞重编程过程,以及(2)中间水平的刚度是
最适合表观遗传重塑和细胞重编程。为了验证我们的假设,我们提出三个
具体目的:(1)研究基质硬度如何通过FA和肌动蛋白调节iN重编程
(2)阐明基质硬度如何调节HAT和表观遗传状态,以开启神经元
iN重编程过程中的基因,和(3)确定肌动蛋白核转运在基质硬度中的作用-
iN重编程过程中HAT和表观遗传状态的调节。我们组织了一个多学科的
拥有机械生物学、细胞工程、高通量基因组学和表观基因组学专业知识的团队
分析和活细胞成像一起工作,并调查潜在的生物物理和生物学
机制等我们提出的研究将是第一个阐明ECM刚度如何调节的研究之一。
细胞重编程的转录组学和表观遗传学变化,以及ECM刚度如何调节局部
粘附和细胞重新编程的细胞骨架。该项目的发现将揭示新的
细胞命运决定的机制,这将在细胞和组织工程中具有广泛的应用,
疾病建模和药物发现,并为优化和开发提供合理的依据,
用于体细胞重编程的新型生物材料。
英文摘要
Project Summary
Cell reprogramming represents a major advancement in biology, and has wide applications in
regenerative medicine, disease modeling and drug screening. During cell reprogramming, cells experience
epigenetic changes that result in a cell phenotype switch. However, whether and how biophysical factors
regulate cell reprogramming through epigenetic modifications are not well understood. We have found that
biophysical factors, specifically extracellular matrix (ECM) stiffness, has profound effects on epigenetic
state and the conversion of fibroblasts into induced neuronal (iN) cells, with the highest efficiency at an
intermediate ECM stiffness, which is regulated by focal adhesions and the cytoskeleton. In addition, we
have discovered that actin assembly and transport into nucleus plays an important role in epigenetic
modulation. Based on our preliminary data, we hypothesize that (1) biophysical cues such as ECM
stiffness regulates FAs, actin assembly/disassembly, nuclear transport of actin, and thus, HAT activity to
modulate the epigenetic state and cell reprogramming process and (2) an intermediate level of stiffness is
optimal for epigenetic remodeling and cell reprogramming. To test our hypothesis, we propose three
Specific Aims: (1) Investigate how matrix stiffness regulates iN reprogramming through FAs and actin
cytoskeleton, (2) Elucidate how matrix stiffness modulates HAT and the epigenetic state to turn on neuronal
genes during iN reprogramming, and (3) Determine the role of actin nuclear transport in matrix stiffness-
modulation of HAT and epigenetic state during iN reprogramming. We have assembled a multidisciplinary
team with expertise on mechanobiology, cell engineering, high throughput genomic and epigenomic
analysis, and live cell imaging to work together and investigate the underlying biophysical and biological
mechanisms. Our proposed studies will be one of the first to elucidate how ECM stiffness regulates
transcriptomic and epigenetic changes for cell reprogramming, and how ECM stiffness modulates focal
adhesions and the cytoskeleton for cell reprogramming. Findings from this project will unravel new
mechanisms of cell fate determination, which will have wide applications in cell and tissue engineering,
disease modeling and drug discovery, and provide a rational basis for the optimization and development of
novel biomaterials for somatic cell reprogramming.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Combination Therapy for Pancreatic Cancer
-
批准号:10581174
-
项目类别:
-
资助金额:$47.26万
-
财政年份:2023
-
负责人:Song Li
-
依托单位:
Nanoparticles-mediated combination therapy for breast cancer
-
批准号:10617544
-
项目类别:
-
资助金额:$51.62万
-
财政年份:2023
-
负责人:Song Li
-
依托单位:
Mechanopriming for cell engineering
-
批准号:10737574
-
项目类别:
-
资助金额:$50.84万
-
财政年份:2023
-
负责人:Song Li
-
依托单位:
Multimodal wireless electrical stimulation for tissue regeneration
-
批准号:10615764
-
项目类别:
-
资助金额:$47.23万
-
财政年份:2022
-
负责人:Song Li
-
依托单位:
Study of Interleukin 33 as a new immunotherapy of lung cancer
-
批准号:10703786
-
项目类别:
-
资助金额:$26.69万
-
财政年份:2022
-
负责人:Song Li
-
依托单位:
Regulation of cell reprogramming by matrix stiffness
-
批准号:10281141
-
项目类别:
-
资助金额:$32.48万
-
财政年份:2021
-
负责人:Song Li
-
依托单位:
Regulation of cell reprogramming by matrix stiffness
-
批准号:10687264
-
项目类别:
-
资助金额:$32.47万
-
财政年份:2021
-
负责人:Song Li
-
依托单位:
Study of Interleukin 33 as a new immunotherapy of lung cancer
-
批准号:10442707
-
项目类别:
-
资助金额:$8.14万
-
财政年份:2019
-
负责人:Song Li
-
依托单位:
Study of Interleukin 33 as a new immunotherapy of lung cancer
-
批准号:10202507
-
项目类别:
-
资助金额:$35.54万
-
财政年份:2019
-
负责人:Song Li
-
依托单位:
Platelets-Mediated Delivery of Checkpoint Inhibitors for Post-Surgical Cancer Immunotherapy
-
批准号:10668316
-
项目类别:
-
资助金额:$39.49万
-
财政年份:2019
-
负责人:Song Li
-
依托单位:
Platelets-Mediated Delivery of Checkpoint Inhibitors for Post-Surgical Cancer Immunotherapy
-
批准号:10206060
-
项目类别:
-
资助金额:$41.4万
-
财政年份:2019
-
负责人:Song Li
-
依托单位:
Therapeutic microneedles for localized treatment of periodontal tissue
-
批准号:10008033
-
项目类别:
-
资助金额:$28.56万
-
财政年份:2019
-
负责人:Song Li
-
依托单位:
Platelets-Mediated Delivery of Checkpoint Inhibitors for Post-Surgical Cancer Immunotherapy
-
批准号:10426123
-
项目类别:
-
资助金额:$39.49万
-
财政年份:2019
-
负责人:Song Li
-
依托单位:
Study of Interleukin 33 as a new immunotherapy of lung cancer
-
批准号:10654777
-
项目类别:
-
资助金额:$43.35万
-
财政年份:2019
-
负责人:Song Li
-
依托单位:
Towards Glucose Transporter-Mediated Glucose-Responsive Insulin Delivery with Fast Response
-
批准号:10425401
-
项目类别:
-
资助金额:$41.88万
-
财政年份:2018
-
负责人:Song Li
-
依托单位:
Nanotherapeutics for Synergistic Targeting of Myc in Prostate Cancer
-
批准号:10063859
-
项目类别:
-
资助金额:$35.7万
-
财政年份:2017
-
负责人:Song Li
-
依托单位:
Nanotherapeutics for Synergistic Targeting of Myc in Prostate Cancer
-
批准号:10307546
-
项目类别:
-
资助金额:$34.98万
-
财政年份:2017
-
负责人:Song Li
-
依托单位:
In Situ Regeneration of Blood Vessel
-
批准号:9022513
-
项目类别:
-
资助金额:$42.34万
-
财政年份:2015
-
负责人:Song Li
-
依托单位:
Nanomicellar Formulation for Synergistic Targeting of Prostate Cancer
-
批准号:8530621
-
项目类别:
-
资助金额:$19.9万
-
财政年份:2013
-
负责人:Song Li
-
依托单位:
Rational Design of Lipidic Vectors for Mitochondria-Targeted Antioxidants
-
批准号:8689109
-
项目类别:
-
资助金额:$28.68万
-
财政年份:2013
-
负责人:Song Li
-
依托单位:
海外基金